Antigenic differences between equine influenza virus vaccine strains and Florida sublineage clade 1 strains isolated in Europe in 2019. (June 2021)

• Record Type: Journal Article
• Authors: Nemoto, Manabu; Ohta, Minoru; Yamanaka, Takashi; Kambayashi, Yoshinori; Bannai, Hiroshi; Tsujimura, Koji; Yamayoshi, Seiya; Kawaoka, Yoshihiro; Cullinane, Ann
• Is Part Of: Veterinary journal. Volume 272(2021)
• Publication Date: 2021-06
• Subjects: Equine influenza virus -- Florida sublineage clade 1 -- Neutralization test -- Reverse genetics -- Vaccine; Veterinary medicine -- Periodicals; 636
• DOI: 10.1016/j.tvjl.2021.105674
• Languages: English
• ISSNs: 1090-0233

Abstract

Highlights: Equine Influenza Virus (EIV) is divided into lineages, sublineages and clades. The Florida sublineage has two clades (Fc1 and Fc2) with a worldwide distribution. Florida sublineage clade 1 (Fc1) caused many EIV outbreaks in Europe in 2019. The antigenicity of Fc1 strains was evaluated by virus neutralization test. Antigenicity of 2019 European Fc1 strains is slightly changed from vaccine strains. Abstract: From late 2018 to 2019, equine influenza virus (EIV) strains of Florida sublineage clade 1 (Fc1), which had until then been circulating mainly in the United States, suddenly spread across Europe causing many outbreaks, and Florida sublineage clade 2 (Fc2) strains, which had been circulating mainly in Europe, have not been detected in Europe since 2018. Since 2010, the World Organisation for Animal Health (OIE) has recommended that EIV vaccines contain an Fc1 strain that is like A/equine/South Africa/4/2003 or A/equine/Ohio/2003. Accordingly, Japanese vaccines contain A/equine/Ibaraki/1/2007 as the Fc1 strain. To evaluate the effectiveness of these vaccines against the Fc1 strains detected in Europe in 2019, we performed virus neutralization tests using horse antisera. Challenge viruses used were Irish strain A/equine/Tipperary/1/2019 and two recombinant viruses generated by reverse genetics. Recombinant viruses possessing hemagglutinin (HA) and neuraminidase (NA) derived from A/equine/Tipperary/1/2019 (rA/equine/Tipperary/1/2019) or British strain A/equine/Essex/1/2019 (rA/equine/Essex/1/2019) were generated. Equine antisera against A/equine/South Africa/2003 and A/equine/Ibaraki/2007 were produced by experimental infection. Antibody titers against A/equine/Tipperary/1/2019, rA/equine/Tipperary/1/2019, and rA/equine/Essex/1/2019 were 2.5- to 6.3-fold lower than those against the homologous vaccine strains A/equine/South Africa/4/2003 or A/equine/Ibaraki/2007. These results suggest that the ongoing evolution of the Fc1 viruses may impact on antigenicity and although antibodies against current vaccine strains neutralize the 2019 strains, ongoing surveillance is essential for optimum choice of candidate vaccine strains.